Interview: AstraZeneca ‘Is More Than Oncology’
AZ’s BioPharma Unit Head Points To CVRM And Respiratory Promise
Ruud Dobber oversees AstraZeneca’s biopharmaceuticals division, which generates some 40% of group total revenues. He tells Scrip to “Watch this space.”
You may also be interested in...
Cardiovascular outcome trials are driving development in blockbuster SGLT-2 inhibitor and GLP-1 agonist classes to look beyond HbA1c levels to focus on cardiovascular and renal protective effects.
Vifor has boosted its US nephrology prospects with a pact with Janssen to jointly market Invokana in diabetic kidney disease.
Revenue from migraine prophylaxis Aimovig shrank from Q2 levels, while cholesterol-lowering Repatha volume increased, but sales came in below consensus.